Galderma reported first-quarter 2026 net sales of $1.47bn, an increase of 25.5% at constant currency. Volume was the predominant driver across all categories, with additional contributions from pricing and product mix.
The Injectable Aesthetics unit grew 13.1% to $648m, with Neuromodulators generating $364m and Fillers reaching $284m as uptake of Relfydess accelerated in Europe and Asia Pacific. U.S. filler sales were aided by favorable order timing and the FDA approval of Restylane Contour for temple hollowing.
Dermatological Skincare revenue rose 17% to $441m, with Cetaphil expanding in international e-commerce channels and Alastin strengthening its U.S. clinic partnerships.
Therapeutic Dermatology sales surged 71.3% to $385m, driven almost entirely by the biologic Nemluvio that contributed $185 million in quarterly sales.
Management reaffirmed full-year 2026 guidance, projecting constant currency net sales growth between 17 and 20% and a Core EBITDA margin near 26%.
